

# Baseline Glycolipid IgG Autoantibodies in GBS Are Prevalent and Show Cross-Regional Pattern Concordance

**Presenter: Susan Halstead**

*Research Associate (Immunology and Infection), University of Glasgow*

**Susan Halstead<sup>1</sup>, Preeti Paliwal<sup>2</sup>, Henk André Kroon<sup>2</sup>, David Lorenz<sup>3</sup>, Zhahirul Islam<sup>4</sup>, Kazim Sheikh<sup>5</sup>, Kenneth C. Gorson<sup>6</sup>, Hugh Willison<sup>1</sup>**

<sup>1</sup>University of Glasgow, Glasgow, UK; <sup>2</sup>Annexon Biosciences, Brisbane, CA, USA; <sup>3</sup>Excelra Inc, Boston, MA, USA; <sup>4</sup>Gut-Brain Axis Laboratory, icddr,b, Dhaka, Bangladesh; <sup>5</sup>McGovern Medical School, UTHealth, Houston, TX, USA; <sup>6</sup>Tufts University School of Medicine, Boston MA, USA

*Tanruprubart (ANX005) is investigational and has not been approved for any indication in any jurisdiction.*

*This study was funded by Annexon Biosciences (Brisbane, CA, USA).*

*Medical writing and editing assistance were provided by Envision Pharma Group and were funded by Annexon Biosciences.*

## Disclosures

**Susan Halstead:** Research funding from Annexon Biosciences and argenx

**Henk-André Kroon:** Employee and shareholder of Annexon Biosciences

**Preeti Paliwal:** Employee and shareholder of Annexon Biosciences

**David Lorenz:** External contractor of Annexon Biosciences to perform data analysis


**Zhahirul Islam:** Research funding from Fogarty International Center, National Institute of Neurological Disorders and Stroke of the National Institutes of Health, USA, and Annexon Biosciences

**Kazim Sheikh:** Research funding from NINDS/NIH and DoD. Consultant for Annexon Biosciences

**Kenneth C. Gorson:** Consultancy/advisory role with Annexon Biosciences, argenx, Janssen, and Sanofi

**Hugh Willison:** Research funding, consultancy payments, and share options from Annexon Biosciences

# Introduction and methods




**Study aim: To evaluate the spectrum and cross-regional concordance of anti-ganglioside IgG signatures in GBS-02 and US cohorts compared with healthy controls**

<sup>a</sup> To assess baseline glycolipid expression


1. Thomma RCM, et al. *Brain*. 2025;148:4000–15.

# Results: Overlapping anti-glycolipid IgG signatures across GBS-02 and US GBS cohorts




**Five antibody clusters conserved across geographical cohorts. Predominant cluster C1 was observed in both populations, indicating cross-regional concordance of antibody-defined GBS biomarkers**  
**AIDP, *C. jejuni*-negative serology, autonomic dysfunction, and lower baseline NfL were enriched within cluster C1 vs other GBS-02 clusters**


# Conclusions



**Autoantibodies to glycolipids were detected in both a GBS-02 (Bangladesh/Philippines) and independent US GBS cohort, consistent with their central role in disease**



**Baseline IgG reactivity patterns were concordant across the GBS-02 and US GBS cohorts**



**These findings support biological comparability across cohorts; further studies linking antibody signatures to complement reactivity, clinical phenotype and outcomes are warranted**

# Acknowledgments

- The study was sponsored by Annexon Biosciences (Brisbane, CA, USA)
- Medical writing and editing assistance were provided by Envision Ignite, an Envision Medical Communications agency, a part of Envision Pharma Group, and were funded by Annexon Biosciences
- The authors would like to thank the study participants

# Thank you